《瑞銀窩輪》匯豐挑戰60港元關口資金流入Put 看淡可留意匯豐認沽22256
港股周二上午時段因藥明(2269)股價大跌,恆指受到拖累走勢向下,下午時段恆指稍有起色,跌幅收窄,全日下跌250點,收報24329點。
是日焦點落在藥明生物,有指美國將藥明系多間關聯企業納入「未經核實」實體名單,認為企業在法規方面存有問題,而藥明則澄清指「未經核實」並不是市場所認知的「黑名單」,對於向全球提供服務並無影響,亦希望可以儘快從名單中剔除。藥明消息傳開後,周一早上藥明股價已下跌近15%,其後跌幅一直擴大,最終於上午時段停牌,股價挫逾22.8%,收報62.25港元。由於藥明股價急跌,市面上大多數牛熊證都被收回,至於藥明相關認股證產品的引伸波幅亦因股價急跌而被抽升,而假如藥明復牌之後股價回順,相關認股證產品的引伸波幅亦會做出相對回調,投資者在選擇相關產品時應時刻留意引伸波幅的變化。
另外,銀行股匯豐(0005)受惠加息預期,股價愈升愈有,周二股價升1.6%,收報58.8港元,續創兩年新高,上望60港元關口。輪場方面較多投資者獲利離場,甚至有投資者部署看淡匯豐,認為匯豐升勢或未能持續。如投資者看淡匯豐,可留意匯豐認沽22256,行使價46.35港元,22年7月到期,有效槓桿約8.3倍。
科技股中阿里(9988)因上周末向美國證委會另註冊10億份ADS的消息,引發市場不同的傳言:如阿里或計劃配股。雖然傳言未獲阿里的確認,周一阿里股價下跌4.5%,截至周二,阿里續跌3.3%,收報111.2港元,為近日跌幅最多的科技股巨頭。由於市場或未能消化阿里另註冊ADS 的消息,加上有大行亦預計短期內阿里股價或會進一步受壓,根據瑞銀近兩個交易日的資金流,較多投資者部署阿里相關認購證博其股價反彈。如投資者看好阿里,可留意阿里認購17474,行使價128.98港元,22年6月到期,有效槓桿約5.1倍。
更多窩輪牛熊資訊:瑞銀認股證牛熊證網站:http://www.ubs.com/hkwarrants
窩證教學及巿焦點況短片:
https://www.youtube.com/channel/UCKw86qy4eBAInmd52MND45Q?view_as=subscriber
謝宛彤
瑞銀亞洲股票衍生產品銷售部
本產品並無抵押品。 如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。筆者為UBS AG的代表(作為證監會持牌人),並未持有相關上市公司的任何財務權益。本資料由瑞銀刊發,其並不構成買賣建議、邀請、要約或遊說。結構性產品價格可急升或急跌,投資者可能會蒙受全盤損失。過往表現並不反映將來表現。牛熊證備強制贖回機制而可能被提早終止,屆時 (i) N類牛熊證投資者將不獲發任何金額;而(ii) R類牛熊證之剩餘價值可能為零。投資前應瞭解有關風險,並諮詢專業顧問及查閱有關上市檔。UBS Securities Hong Kong Limited為結構性產品之流通量提供者,亦可能是唯一報價者或巿場參與者。(C) UBS 2022。版權所有。~
重要聲明:
以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.